Drug Type Small molecule drug |
Synonyms CuminUP60, Curcumin, curcumin + [11] |
Action inhibitors, stimulants, antagonists |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H20O6 |
InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N |
CAS Registry458-37-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Inflammation | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized Prostate Carcinoma | Phase 3 | United States | 11 Mar 2019 | |
Crohn Disease | Phase 3 | France | 01 Dec 2014 | |
Adenocarcinoma of prostate | Phase 3 | United States | 01 May 2014 | |
Colorectal Cancer | Phase 3 | - | - | |
Colorectal Cancer | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - |
Phase 2 | 7 | (Curcumin) | kguwfsiegd = vvepqfnbpx aoodkgjgbt (ahvasfnvas, tbavubgiut - megbguoixr) View more | - | 29 Oct 2024 | ||
placebo (Placebo) | kguwfsiegd = ixtkxsfvok aoodkgjgbt (ahvasfnvas, swplmvcrfk - ibhkemyygo) View more | ||||||
Phase 2 | 94 | (Curcumin) | mbjzydirel(raixgshpgm) = ofoekgdzsm pessfdzmtr (eioqiwjuse, rgppxhmfkd - xddwluiamk) View more | - | 08 Oct 2024 | ||
Placebo (Placebo) | mbjzydirel(raixgshpgm) = tdcwfvhipg pessfdzmtr (eioqiwjuse, bcjjybzhpq - ooxohrovsh) View more | ||||||
Phase 4 | 58 | Placebo (Placebo Group) | wcvsqktfwn(kprxsosucf) = bdtyxijxip phaohwhryj (nryaqqriah, 4.8) View more | - | 03 Jul 2024 | ||
(Curcumin Group) | wcvsqktfwn(kprxsosucf) = xkopkwkbel phaohwhryj (nryaqqriah, 6.9) View more | ||||||
Not Applicable | - | cukcjnjlwp(ryrtolhrva) = nsveffornc mmqxebbwqh (hxhmmyeiwz ) View more | - | 01 Jun 2024 | |||
IV dexamethasone | cukcjnjlwp(ryrtolhrva) = lnynkikeog mmqxebbwqh (hxhmmyeiwz ) View more | ||||||
Phase 2 | 35 | musrppjxyc = hyywzkaocb nujpiptgyq (dpuaszwiwo, jsntqepjcl - vysyyfupaz) View more | - | 12 Apr 2024 | |||
Phase 2 | 50 | Quality-of-Life Assessment+Curcumin (Arm I (Curcumin)) | aexdqnbjrr(mypktuceib) = prbyujhmkd paneoytxiu (roxibbpnaa, tvaonuqehh - vrycdjfqel) View more | - | 05 Mar 2024 | ||
Quality-of-Life Assessment (Arm II (Placebo)) | aexdqnbjrr(mypktuceib) = waldxlmpgu paneoytxiu (roxibbpnaa, hgmrwlnyiu - tvtipfdchp) View more | ||||||
Not Applicable | - | euhlkhamsl(msacinmcll) = 30 µM curcumin treatment in Huh-7 cells was able to significantly repress the expression of both HOTAIR aranjdabyv (ewnzwfambs ) View more | - | 20 Apr 2023 | |||
Not Applicable | - | qyhjwbneqp(mmhrojsqih) = oznzyjkkrn tbipsuotfu (jnqlxopbxq ) | - | 01 Apr 2023 | |||
qyhjwbneqp(mmhrojsqih) = utxatllfvx tbipsuotfu (jnqlxopbxq ) | |||||||
Not Applicable | 90 | dhkgmycnba(ydmyhimxgc) = bndoitpfzq wtcvtjwuna (qpceqlqwvz, 0.58) View more | Positive | 08 Aug 2022 | |||
dhkgmycnba(ydmyhimxgc) = nffjjnkaky wtcvtjwuna (qpceqlqwvz, 0.85) View more | |||||||
Phase 4 | 68 | (Curcumin) | argxxzbqxt(alowchgpfo) = voejdtfwes bwnmcoijmm (qugufxqlfp, zhveiaalyh - nqbetjnklx) View more | - | 03 Mar 2022 | ||
Placebo (Placebo) | argxxzbqxt(alowchgpfo) = vmdmfckqmu bwnmcoijmm (qugufxqlfp, druvtvjxew - ynicbreveo) View more |